Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder

J Clin Invest. 2013 Sep;123(9):3710-2. doi: 10.1172/JCI71220. Epub 2013 Aug 27.

Abstract

In a report reading like a fascinating detective story, Vincent and colleagues crack the mysterious case of east Texas bleeding disorder. They show that affected individuals have a mutation in exon 13 of the coagulation F5 gene that causes increased expression of an alternatively spliced transcript, which encodes a previously unrecognized factor V (FV) isoform they call FV-short. This FV isoform lacks a large portion of the B domain of FV, which is normally released upon the proteolytic activation of FV by thrombin and binds tightly to the coagulation regulator tissue factor pathway inhibitor-α (TFPIα). This interaction leads to an approximately 10-fold increase in the level of TFPIα circulating in plasma and a resultant anticoagulant effect that produces a hemorrhagic diathesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Blood Coagulation Disorders, Inherited / genetics*
  • Factor V / genetics*
  • Hemorrhagic Disorders / genetics*
  • Humans
  • Lipoproteins / blood*

Substances

  • Lipoproteins
  • lipoprotein-associated coagulation inhibitor
  • Factor V